RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
Vislink Appoints Industry Veteran Bill Sweeney as New Managing Director of MilGov Business Segment
January 02, 2024 08:00 ET
|
Vislink Technologies, Inc.
Mt. Olive, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Vislink Technologies, Inc. (“Vislink” or the “Company”) (Nasdaq: VISL), a global technology leader in the capture, delivery, and management of high...
Sono-Tek Completes Senior Management Transition
January 02, 2024 08:00 ET
|
Sono-Tek Corporation
Sono-Tek Completes Senior Management Transition
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
January 02, 2024 08:00 ET
|
atai Life Sciences
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD)...
Anavex Life Sciences Provides an Update on Rett Syndrome Program
January 02, 2024 08:00 ET
|
Anavex Life Sciences Corp.
Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE) of Rett Syndrome Patients under Compassionate Use...
Court Finds Corcept Therapeutics’ Patents Not Infringed
January 02, 2024 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
January 02, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients,...
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
January 02, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora's BioJet™ drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study.